Covid-19 has bought many biotech companies into the limelight, all promising a possible solution to the pandemic that has disrupted lives worldwide. In February 2021, Ocugen, Inc. (NASDAQ: OCGN) shares catapulted after news of the Company signing a binding letter of intent (LOI) with Bharat...
MediWound Ltd (NASDAQ: MDWD), a Company creating cutting-edge solutions for tissue repair and regeneration, recently announced its Q4 and Full-year 2020 Financial results. While the revenue was up by 23 percent, at $6.7 Million, compared to $5.4 million for the same period in 2019, product revenues...
Sesen Bio, Inc. (NASDAQ: SESN) is focused on creating targeted fusion protein therapeutics (TFPTs) for treatment of cancers. The Company is looking at a major catalyst in 2021, the approval of Vicineum, a potential best-in-class therapeutic for the treatment of non-muscle invasive bladder cancer (NMIBC)...
Albireo Pharma, Inc. (NASDAQ: ALBO) a clinical-stage company targeting rare liver diseases, announced the acceptance of its New Drug Application (NDA) for odevixibat, a once-daily, non-systemic IBAT, intended for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The candidate is also...
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device Company leveraging its signal processing technology platform, announced its partnership with Vuzix® Corporation (NASDAQ: VUZI), to deploy Vuzix’s M400 Smart Glasses for remote servicing, installations, upgrades and training of its PURE EP™ System, to support a nationwide...
While Industries across the globe are grappling with the pandemic and its impact on their operations, Biotech Industry has been focused on minimizing the impact and marching ahead with its innovations and breakthroughs. We take a look at some Biotech’s that are impervious to the scare...
Inovio Pharmaceuticals (NASDAQ: INO), a late-stage biotechnology Company developing DNA-based immunotherapies and vaccines to combat cancer and infectious diseases, announced the grant of up to $9 million by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for Coronavirus 2019-nCoV, a deadly new...
Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical Company engaged in developing candidates for oncology, auto-immune and chronic pain, has announced the withdrawal of its application for oxycodegol (formerly NKTR-181), as it received adverse advisory committee decision from both Anesthetic and Analgesic Drug Products Advisory Committee, and...
ChromaDex (NASDAQ: CDXC), a nutraceutical Company focussed on improving the way people age, announced the launch of a “first-of-its-kind” Phase 1 clinical study to test the safety, efficacy and potential of branded nicotinamide riboside (NR), Niagen, in improving the effects of exercise therapy in older...
BrainStorm Cell Therapeutics (NASDAQ: BCLI), a Company focussed on developing autologous cellular therapies for neurodegenerative diseases, has been awarded the Buzz of Bio 2020 in the public therapeutic biotech category. The award recognises the efforts of Brainstorm in the field of neurodegenerative diseases, including progressive...
